Annexon Dirección
Dirección controles de criterios 4/4
El CEO de Annexon es Doug Love , nombrado en Dec 2014, tiene una permanencia de 9.92 años. compensación anual total es $2.45M, compuesta por 24.2% salario y 75.8% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.28% de las acciones de la empresa, por valor de $1.53M. La antigüedad media del equipo directivo y de la junta directiva es de 2.5 años y 6.1 años, respectivamente.
Información clave
Doug Love
Chief Executive Officer (CEO)
US$2.5m
Compensación total
| Porcentaje del salario del CEO | 24.2% |
| Permanencia del CEO | 9.9yrs |
| Participación del CEO | 0.3% |
| Permanencia media de la dirección | 2.5yrs |
| Promedio de permanencia en la Junta Directiva | 6.1yrs |
Actualizaciones recientes de la dirección
Recent updates
We're Hopeful That Annexon (NASDAQ:ANNX) Will Use Its Cash Wisely
Sep 27
Speculative "Buy" Rating On Annexon: Evaluating The Potential Of ANX005 For GBS
Aug 17Annexon: Complement Inhibition Of GBS Only The Beginning With Strong Tech In Place
Jun 04Annexon: Unforced Error Sullies Prospects
Apr 03Here's Why We're Watching Annexon's (NASDAQ:ANNX) Cash Burn Situation
Nov 10Is Annexon (NASDAQ:ANNX) In A Good Position To Deliver On Growth Plans?
Jul 25Is Annexon (NASDAQ:ANNX) In A Good Position To Deliver On Growth Plans?
Apr 11Are Investors Undervaluing Annexon, Inc. (NASDAQ:ANNX) By 25%?
Feb 14We Think Annexon (NASDAQ:ANNX) Needs To Drive Business Growth Carefully
Dec 28Annexon started as a buy at Jefferies on market potential of candidates, data catalysts
Sep 16Annexon: A First Take
Aug 21Annexon Biosciences GAAP EPS of -$0.96 misses by $0.02
Aug 08Annexon to raise $130M in stock and warrant offering
Jul 08We're Keeping An Eye On Annexon's (NASDAQ:ANNX) Cash Burn Rate
Apr 16Companies Like Annexon (NASDAQ:ANNX) Are In A Position To Invest In Growth
Jan 01Companies Like Annexon (NASDAQ:ANNX) Are In A Position To Invest In Growth
Sep 08We Think Annexon (NASDAQ:ANNX) Can Afford To Drive Business Growth
May 22We Think Annexon (NASDAQ:ANNX) Can Afford To Drive Business Growth
Feb 06
Dosing underway in Annexon's Phase 2/3 study of monoclonal antibody in Guillain-Barré Syndrome
Dec 21Annexon Biosciences EPS misses by $0.43
Nov 16Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$118m |
| Jun 30 2024 | n/a | n/a | -US$115m |
| Mar 31 2024 | n/a | n/a | -US$121m |
| Dec 31 2023 | US$2m | US$593k | -US$134m |
| Sep 30 2023 | n/a | n/a | -US$141m |
| Jun 30 2023 | n/a | n/a | -US$143m |
| Mar 31 2023 | n/a | n/a | -US$145m |
| Dec 31 2022 | US$4m | US$569k | -US$142m |
| Sep 30 2022 | n/a | n/a | -US$145m |
| Jun 30 2022 | n/a | n/a | -US$145m |
| Mar 31 2022 | n/a | n/a | -US$140m |
| Dec 31 2021 | US$8m | US$534k | -US$130m |
| Sep 30 2021 | n/a | n/a | -US$116m |
| Jun 30 2021 | n/a | n/a | -US$103m |
| Mar 31 2021 | n/a | n/a | -US$84m |
| Dec 31 2020 | US$5m | US$446k | -US$70m |
| Sep 30 2020 | n/a | n/a | -US$56m |
| Jun 30 2020 | n/a | n/a | -US$45m |
| Mar 31 2020 | n/a | n/a | -US$42m |
| Dec 31 2019 | US$3m | US$396k | -US$38m |
| Sep 30 2019 | n/a | n/a | -US$34m |
| Jun 30 2019 | n/a | n/a | -US$28m |
| Mar 31 2019 | n/a | n/a | -US$23m |
| Dec 31 2018 | US$518k | US$379k | -US$18m |
Compensación vs. Mercado: La compensación total ($USD2.45M) de Doug está en línea con el promedio de empresas de tamaño similar en el mercado US ($USD2.14M).
Compensación vs. Ingresos: La compensación de Doug ha sido consistente con los resultados de la empresa en el último año.
CEO
Doug Love (56 yo)
9.9yrs
Permanencia
US$2,453,184
Compensación
Mr. Douglas Love, Esq., J.D, also known as Doug, has been the President, Director and Chief Executive Officer of Annexon Inc. since December 2014. He has extensive business and legal leadership experience...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO, President & Director | 9.9yrs | US$2.45m | 0.28% $ 1.5m | |
| Chief Scientific Officer & Executive VP | 1.8yrs | US$1.83m | 0.047% $ 258.7k | |
| Executive VP | 3.1yrs | US$1.14m | 0.067% $ 366.8k | |
| Executive VP | 5.4yrs | US$1.44m | 0.026% $ 141.5k | |
| Executive VP & Chief Business Officer | 4.3yrs | US$1.40m | 0.033% $ 183.4k | |
| Senior Vice President of Translational Medicine | no data | sin datos | sin datos | |
| Executive VP & Chief Medical Officer | 1.3yrs | sin datos | sin datos | |
| Senior VP & Head of Commercial | less than a year | sin datos | sin datos | |
| Senior VP of Medical Affairs | less than a year | sin datos | sin datos |
2.5yrs
Permanencia media
59.5yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de ANNX se considera experimentado (2.5 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO, President & Director | 9.9yrs | US$2.45m | 0.28% $ 1.5m | |
| Executive VP | less than a year | US$1.14m | 0.067% $ 366.8k | |
| Independent Director | 9.9yrs | US$103.93k | 0.76% $ 4.1m | |
| Independent Chairman | 7.8yrs | US$132.43k | 0.00025% $ 1.4k | |
| Independent Director | 4.4yrs | US$100.93k | 0% $ 0 | |
| Independent Director | 3.3yrs | US$103.43k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos |
6.1yrs
Permanencia media
66yo
Promedio de edad
Junta con experiencia: La junta directiva de ANNX se considera experimentada (6.1 años de antigüedad promedio).